The effect of ivabradine tablets combined with milrinone on arterial blood flow and cTnI in patients with acute myocardial infarction combined with heart failure

Objective: To investigate the effects of ivabradine tablets combined with milrinone on arterial blood flow and cTnI in patients with acute myocardial infarction (AMI) combined with heart failure (HF). Methods: A randomised double-blind, placebo-parallel controlled clinical study protocol was adopted to select 78 patients with AMI combined with HF who attended the cardiology care unit of our hospital from January 2022 to January 2024, and randomly divided them into 2 groups of 39 patients each. Both groups were given conventional treatment, with Bmilrinone combined with placebo for oral administration in the control group and milrinone combined with ivabradine hydrochloride tablets for oral administration in the observation group. Compare the clinical efficacy and the occurrence of adverse reactions between the two groups. Compare the arterial blood flow indexes [cardiac index (CI), left ventricular ejection fraction (LVEF), global end-diastolic volume index (GEDVI), systemic vascular resistance index (SVRI), early diastolic/late diastolic LV valvular flow velocity (E/A ratio)], cardiac enzymology indexes [cardiac troponin I (cTnI), troponin T (cTnT)], and cardiac enzymes [cardiac troponin I (cTnI), troponin T (cTnT)] in the 2 groups before and after treatment, lactate dehydrogenase (LDH), creatine kinase isoenzyme (CK-MB)], circulating endocrine hormone levels [renin activity (PRA), angiotensin II (Ang II), aldosterone (Ald)] and quality of life scoring indexes [Seattle Angina Scale (SAQ), Pittsburgh Sleep Quality Index (PSQI)]. Results: After treatment, the total clinical effectiveness rate of the observation group (87.18%) was significantly higher than that of the control group (66.67%) (P < 0.05). The CI, LVEF, E/A ratio and SAQ scores of the observation group were significantly higher than those of the control group, and the scores of GEDVI, SVRI, cTnI, cTnT, LDH, CK-MB, PRA, Ang II, Ald and PSQI were significantly lower than those of the control group, which were significantly different (P < 0.05). There was no significant difference in the comparison of the incidence of adverse reactions between the 2 groups (P > 0.05) The incidence of adverse reactions in the 2 groups was not significantly different (P > 0.05). Conclusion: Ivabradine tablets combined with milrinone in the treatment of AMI combined with HF patients with significant efficacy, can effectively reduce myocardial injury, stabilise arterial haemodynamics, improve the cardiac function of the patients, and does not increase the adverse effects of drugs.